These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10588838)

  • 21. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
    Jacquemin E; Hermans D; Myara A; Habes D; Debray D; Hadchouel M; Sokal EM; Bernard O
    Hepatology; 1997 Mar; 25(3):519-23. PubMed ID: 9049190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
    Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
    Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Jeune'disease (asphyxiating thoracic dystrophy) and respiratory failure: importance of early respiratory management with periodic hyperinsufflation].
    Do Ngoc Thanh C; Barois A; Estournet-Mathiaud B; Bataille J; Ioos C
    Bull Acad Natl Med; 2007 Oct; 191(7):1411-29; discussion 1429-32. PubMed ID: 18447062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 25. Jeune syndrome (asphyxiating thoracic dystrophy) associated with Hirschsprung disease.
    Aurora P; Wallis CE
    Clin Dysmorphol; 1999 Oct; 8(4):259-63. PubMed ID: 10532174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct hyperbilirubinemia and hepatic fibrosis: a new presentation of Jeune syndrome (asphyxiating thoracic dystrophy).
    Whitley CB; Schwarzenberg SJ; Burke BA; Freese DK; Gorlin RJ
    Am J Med Genet Suppl; 1987; 3():211-20. PubMed ID: 3130856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
    Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F
    Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical quiz. Jeune syndrome.
    Jankauskiené A; Bernatoniené J
    Pediatr Nephrol; 2000 Sep; 14(10-11):1054-6. PubMed ID: 10975324
    [No Abstract]   [Full Text] [Related]  

  • 29. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of autoimmune hepatitis in primary biliary cirrhosis.
    Gossard AA; Lindor KD
    Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obstetric cholestasis characterized by extremely elevated serum transaminases.
    Karamouti M; Gerovasilis F; Georgadakis G
    Int J Gynaecol Obstet; 2007 Aug; 98(2):157-8. PubMed ID: 17588573
    [No Abstract]   [Full Text] [Related]  

  • 32. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
    Dehtiar'ova II; Chernenko VV; Anokhina HA; Opanasiuk ND; Pavlik-Novol's'kyĭ T; Haĭsenko AV
    Lik Sprava; 1995; (9-12):47-8. PubMed ID: 8983789
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis.
    Alenezi B; Lamoureux E; Alpert L; Szilagyi A
    Dig Dis Sci; 2005 Jan; 50(1):196-200. PubMed ID: 15712660
    [No Abstract]   [Full Text] [Related]  

  • 36. Asphyxiating thoracic dystrophy with facial dysmorphism.
    Sankar VH; Phadke SR
    Indian J Pediatr; 2006 Dec; 73(12):1115-8. PubMed ID: 17202643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The assessment of liver function in occupational exposure to divinyl].
    Mikhaĭlova A; Ivanova-Chemishanska L; Ilieva P; Khandzhieva M; Gincheva N
    Probl Khig; 1991; 16():81-6. PubMed ID: 1686652
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
    Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
    Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Transaminase disorders in asphyxiated term infants: a good neurological marker?].
    Gonzalez de Dios J
    Rev Neurol; 2004 Feb 1-15; 38(3):299-300; author reply 300. PubMed ID: 14963862
    [No Abstract]   [Full Text] [Related]  

  • 40. Titration of bile acid supplements in 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase/isomerase deficiency.
    Riello L; D'Antiga L; Guido M; Alaggio R; Giordano G; Zancan L
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):655-60. PubMed ID: 20400917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.